Showing Results for: “diabetes exercise”

Today, findings from two phase 2 clinical trials showcase new data for an investigational, once-weekly injectable glucose-dependent insulinotropic polypeptide (GIP)/ glucagon-like peptide 1 (GLP-1) /glucagon (GCG) receptor agonist, retatrutide. One study was conducted in people with obesity and included a substudy in patients who also had non-alcoholic fatty liver disease (NAFLD) and the second study included patients with type 2 diabetes (T2D). These studies were presented during the symposium entitled “Retatrutide (LY3437943), a Novel GIP/GLP 1/Glucagon Receptor Triagonist—Obesity, NAFLD

The American Diabetes Association® (ADA) will present the 2019 Harold Rifkin Award for Distinguished International Service in the Cause of Diabetes to Juliana C.N. Chan, MB, ChB, MD, FRCP. This award honors individual outstanding service in the cause of diabetes, performed with an international perspective and with international impact. Dr. Chan will be recognized with this honor at the National Scientific and Health Care Achievement Awards Presentation on Monday, June 10, during the ADA’s 79th Scientific Sessions, June 7-11, 2019, at the Moscone Convention Center in San Francisco. Dr. Chan is

A medida que la Costa del Golfo experimenta el impacto de huracán Laura, la comunidad de diabetes se une para asegurarse de que las personas que viven con diabetes, especialmente aquellas que dependen de insulina, reciban el apoyo necesario. La Diabetes Disaster Response Coalition (DDRC), está compuesta por las principales organizaciones de diabetes del país, insta a todas las personas con diabetes y a sus seres queridos a comunicarse si experimentan escasez de suministros para el manejo de diabetes y si necesitan información acerca de cómo mantenerse saludables y seguros. Las grandes

Latest results report long-term impacts of lifestyle intervention and metformin treatment on people enrolled in the NIDDK-supported study Long-term follow-up of more than 2,000 people enrolled in the Diabetes Prevention Program Outcomes Study (DPPOS) indicates a continued significant reduction in the participants’ risk of developing type 2 diabetes (T2D). Today’s “New Data on Clinical Outcomes from the Diabetes Prevention Program Outcomes Study (DPPOS)” symposium outlined the latest research results of the study at the American Diabetes Association’s® (ADA’s) 80th Virtual Scientific Sessions

The American Diabetes Association’s Chief Executive Officer Charles D. “Chuck” Henderson issued the following statement on the passing of Congressman Donald Payne Jr. “This week, the diabetes community lost a true champion as we learned of the passing of Congressman Donald Payne Jr. Congressman Payne Jr. embodied the highest standards of public service and was a champion for people living in his district and in New Jersey. He was a leader amongst his peers and frequently spoke about his own health challenges with diabetes and related conditions, as he fought to ensure that others achieved

As Minority Health Month draws to a close, the American Diabetes Association® (ADA) highlighted progress towards health equity in its 2023 Health Equity Impact Report . There are 136 million Americans are living with diabetes or prediabetes and those living in under-resourced communities are more likely to develop diabetes and experience its associated complications. The ADA is striving to build awareness around the disproportionate burden people face when it comes to diabetes care and is working in communities across the country to increase equitable access. “Guided by the ADA’s Healthy

Findings Reveal Efficacy of Novel Inhaler to Improve Glycemic Control for Patients with Type 1 Diabetes Today, findings from INHALE-3, a pivotal trial examining the use of inhaled insulin in adults with type 1 diabetes (T1D), were announced, highlighting the potential of an alternative insulin solution to enhance diabetes management. The results were presented as a symposium at the 84th Scientific Sessions of the American Diabetes Association® (ADA) in Orlando, FL. Type 1 diabetes affects 11.6% of the American population and millions of individuals globally , requiring ongoing insulin therapy

“Access to affordable diabetes medications and technology can help people living with diabetes stay healthy and avoid complications. Sadly, some of the 37.3 million Americans living with diabetes can’t afford the treatments they need to survive,” said Charles “Chuck” Henderson, chief executive officer of the American Diabetes Association ® (ADA). “The ADA has been the leading voice in advocating for affordable insulin and diabetes technology. We applaud Amazon Pharmacy for innovating on behalf of people with diabetes and taking important action to help ensure they easily access the treatments

For 74 years, National Summer Camps Have Equipped Children with Diabetes and Their Families with Diabetes Management Tools in Safe and Fun-Filled Environment Registration is open for the American Diabetes Association ® (ADA) 2023 summer camp season. The ADA runs 33 camps located in 20 states throughout the summer season, June through August. ADA camps provide a medically safe environment where children with diabetes and their families can partake in a fun-filled summer camp experience while learning how to better manage diabetes. ADA camps also serve as a connecting point for children to